NASDAQ:CYCC Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis $0.34 -0.01 (-3.66%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CYCC alerts:Sign Up Key Stats Today's Range$0.32▼$0.3550-Day Range$0.28▼$5.6652-Week Range$0.25▼$39.84Volume408,657 shsAverage Volume421,059 shsMarket Capitalization$7.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company OverviewCyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Read More… Cyclacel Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreCYCC MarketRank™: Cyclacel Pharmaceuticals scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Cyclacel Pharmaceuticals.Read more about Cyclacel Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cyclacel Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cyclacel Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cyclacel Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.67% of the float of Cyclacel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyclacel Pharmaceuticals has recently increased by 1,759.69%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCyclacel Pharmaceuticals does not currently pay a dividend.Dividend GrowthCyclacel Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.67% of the float of Cyclacel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyclacel Pharmaceuticals has recently increased by 1,759.69%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News Sentiment0.94 News SentimentCyclacel Pharmaceuticals has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cyclacel Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 4 people have searched for CYCC on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cyclacel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cyclacel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders96.90% of the stock of Cyclacel Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 23.58% of the stock of Cyclacel Pharmaceuticals is held by institutions.Read more about Cyclacel Pharmaceuticals' insider trading history. Receive CYCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CYCC Stock News HeadlinesCyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred StockJune 20, 2025 | globenewswire.comCYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENTJune 3, 2025 | globenewswire.comAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new invention… This could send many popular AI stocks crashing, including Nvidia. And it could happen starting as soon as June 1st.June 27 at 2:00 AM | Paradigm Press (Ad)CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATEMay 14, 2025 | globenewswire.comCyclacel Pharmaceuticals, Inc.: Cyclacel Pharmaceuticals Announces Stock SplitMay 9, 2025 | finanznachrichten.deCYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLITMay 7, 2025 | globenewswire.comCYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.May 6, 2025 | globenewswire.comCyclacel Pharmaceuticals files to sell 35.18M shares of common stock for holdersApril 27, 2025 | markets.businessinsider.comSee More Headlines CYCC Stock Analysis - Frequently Asked Questions How have CYCC shares performed this year? Cyclacel Pharmaceuticals' stock was trading at $6.0160 at the beginning of the year. Since then, CYCC stock has decreased by 94.4% and is now trading at $0.3370. View the best growth stocks for 2025 here. How were Cyclacel Pharmaceuticals' earnings last quarter? Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) posted its quarterly earnings results on Wednesday, April, 2nd. The biotechnology company reported ($5.28) earnings per share for the quarter, missing the consensus estimate of ($4.64) by $0.64. The biotechnology company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative trailing twelve-month return on equity of 3,648.09%. When did Cyclacel Pharmaceuticals' stock split? Shares of Cyclacel Pharmaceuticals reverse split before market open on Monday, May 12th 2025.The 1-16 reverse split was announced on Wednesday, May 7th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 9th 2025. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. Who are Cyclacel Pharmaceuticals' major shareholders? Top institutional investors of Cyclacel Pharmaceuticals include Armistice Capital LLC (0.61%). Insiders that own company stock include Spiro George Rombotis, Paul Mcbarron and David E Lazar. View institutional ownership trends. How do I buy shares of Cyclacel Pharmaceuticals? Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cyclacel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclacel Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and Arista Networks (ANET). Company Calendar Last Earnings4/02/2025Record date for 5/1 Dividend4/29/2025Ex-Dividend for 5/1 Dividend4/29/2025Dividend Payable5/01/2025Today6/27/2025Next Earnings (Estimated)7/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CYCC CIK1130166 Webwww.cyclacel.com Phone(908) 517-7330Fax866-271-3466Employees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($56.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.21 million Net Margins-18,150.00% Pretax Margin-55,535.71% Return on Equity-3,648.09% Return on Assets-155.99% Debt Debt-to-Equity RatioN/A Current Ratio5.60 Quick Ratio5.60 Sales & Book Value Annual Sales$40 thousand Price / Sales196.33 Cash FlowN/A Price / Cash FlowN/A Book Value($3.93) per share Price / Book-0.09Miscellaneous Outstanding Shares22,450,000Free Float696,000Market Cap$7.85 million OptionableOptionable Beta0.24 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CYCC) was last updated on 6/27/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.